Telix Pharmaceuticals (TLX1N) Financial Statements
Telix Pharmaceuticals Financial Overview
Telix Pharmaceuticals's market cap is currently $59.00B. The company's EPS TTM is $0.10; its P/E ratio is 96.62; Telix Pharmaceuticals is estimated to report earnings on February 19, 2027, and the estimated EPS forecast is $1.12. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 816.72M | $ 783.21M | $ 502.55M | $ 160.10M | $ 7.60M |
| Gross Profit | $ 433.78M | $ 509.68M | $ 314.39M | $ 29.34M | $ -29.77M |
| Operating Income | $ 18.05M | $ 82.13M | $ 52.63M | $ -73.18M | $ -81.25M |
| EBITDA | $ 40.18M | $ 90.10M | $ 23.15M | $ -92.84M | $ -70.07M |
| Net Income | $ -7.24M | $ 49.92M | $ 5.21M | $ -104.08M | $ -80.51M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 141.96M | $ 710.35M | $ 123.24M | $ 116.33M | $ 22.04M |
| Total Assets | $ 1.18B | $ 1.52B | $ 406.32M | $ 255.35M | $ 109.81M |
| Total Debt | $ 466.96M | $ 581.45M | $ 17.45M | $ 10.45M | $ 2.54M |
| Net Debt | $ 325.00M | $ -128.90M | $ -105.79M | $ -105.88M | $ -19.50M |
| Total Liabilities | $ 767.25M | $ 948.22M | $ 255.89M | $ 175.35M | $ 106.17M |
| Stockholders' Equity | $ 415.66M | $ 568.21M | $ 148.91M | $ 80.01M | $ 2.16M |
| Cash Flow | |||||
| Free Cash Flow | $ -56.10M | $ 9.00M | $ 13.09M | $ -77.83M | $ -60.67M |
| Operating Cash Flow | $ -17.57M | $ 43.03M | $ 23.88M | $ -63.97M | $ -59.33M |
| Investing Cash Flow | $ -290.52M | $ -135.17M | $ -25.49M | $ -17.00M | $ -2.73M |
| Financing Cash Flow | $ -3.78M | $ 638.92M | $ 10.19M | $ 174.96M | $ 2.85M |
Currency in AUD
